IL109605A - Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them - Google Patents

Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them

Info

Publication number
IL109605A
IL109605A IL10960594A IL10960594A IL109605A IL 109605 A IL109605 A IL 109605A IL 10960594 A IL10960594 A IL 10960594A IL 10960594 A IL10960594 A IL 10960594A IL 109605 A IL109605 A IL 109605A
Authority
IL
Israel
Prior art keywords
alkyl
hydrogen
diagnostics
oligonucleotides
pharmaceutical compositions
Prior art date
Application number
IL10960594A
Other languages
English (en)
Other versions
IL109605A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IL12333094A priority Critical patent/IL123330A/xx
Publication of IL109605A0 publication Critical patent/IL109605A0/xx
Priority to IL12333098A priority patent/IL123330A0/xx
Publication of IL109605A publication Critical patent/IL109605A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
IL10960594A 1993-05-12 1994-05-10 Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them IL109605A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12333094A IL123330A (en) 1993-05-12 1994-05-10 Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them
IL12333098A IL123330A0 (en) 1993-05-12 1998-02-17 Nucleosides having 2'-ether group their preparation and their use in the production of oligonucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH146793 1993-05-12

Publications (2)

Publication Number Publication Date
IL109605A0 IL109605A0 (en) 1994-08-26
IL109605A true IL109605A (en) 1999-12-31

Family

ID=4211171

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12333094A IL123330A (en) 1993-05-12 1994-05-10 Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them
IL10960594A IL109605A (en) 1993-05-12 1994-05-10 Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them
IL12333098A IL123330A0 (en) 1993-05-12 1998-02-17 Nucleosides having 2'-ether group their preparation and their use in the production of oligonucleotides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12333094A IL123330A (en) 1993-05-12 1994-05-10 Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12333098A IL123330A0 (en) 1993-05-12 1998-02-17 Nucleosides having 2'-ether group their preparation and their use in the production of oligonucleotides

Country Status (11)

Country Link
US (1) US5969116A (es)
EP (1) EP0626387B1 (es)
JP (1) JP4012579B2 (es)
CN (1) CN1100728A (es)
AT (1) ATE177430T1 (es)
AU (1) AU687796B2 (es)
CA (1) CA2123241C (es)
DE (1) DE59407895D1 (es)
DK (1) DK0626387T3 (es)
ES (1) ES2128535T3 (es)
IL (3) IL123330A (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) * 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
TR199801581T2 (xx) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
ATE251638T1 (de) 1996-06-06 2003-10-15 Novartis Pharma Gmbh 2-substituierte nukleosid- und oligonukleotid- derivate
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
EP0979309A4 (en) * 1997-04-30 2000-10-18 Isis Pharmaceuticals Inc OLIGONUCLEOTIDES WITH IMPROVED BIOAVAILABILITY
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6093807A (en) * 1999-03-19 2000-07-25 Isis Pharmaceuticals, Inc. Sugar-modified 7-deaza-7-substituted oligonucleotides
AU2001292142A1 (en) * 2000-09-11 2002-03-22 Affymetrix, Inc. Photocleavable protecting groups
US20030027169A1 (en) * 2000-10-27 2003-02-06 Sheng Zhang One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
US7547775B2 (en) * 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
US8097597B2 (en) 2005-05-05 2012-01-17 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors
RU2483057C2 (ru) 2006-06-28 2013-05-27 Ньюселис Инк. Смеси жирных кислот и их применение
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
ES2641290T3 (es) 2007-11-20 2017-11-08 Ionis Pharmaceuticals, Inc Modulación de la expresión de CD40
WO2009068617A1 (en) 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
WO2009102427A2 (en) 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
CN102264374B (zh) 2008-10-24 2015-01-07 Isis制药公司 5′和2′双取代的核苷和由其制备的低聚化合物
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP5542196B2 (ja) 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
EP3091027B1 (en) 2010-04-28 2018-01-17 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
PE20130602A1 (es) 2010-08-12 2013-05-25 Boehringer Ingelheim Int Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
EP2453017A1 (en) 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) * 2011-09-19 2016-02-10 上海兆维科技发展有限公司 2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
WO2014178082A1 (en) * 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research Novel 2'/3'/5'-(r/s)-serinyl functionalized oligonucleotides
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3079707A4 (en) 2013-12-02 2017-10-18 RXi Pharmaceuticals Corporation Immunotherapy of cancer
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
JP6983752B2 (ja) 2015-07-06 2021-12-17 フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. スーパーオキシドディスムターゼ１（ｓｏｄ１）を標的とする核酸分子
CA3002744A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017142054A1 (ja) 2016-02-17 2017-08-24 国立大学法人東京工業大学 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
CA3087266A1 (en) 2018-01-09 2019-07-18 Cibus Us Llc Shatterproof genes and mutations
BR112020018902A2 (pt) 2018-03-20 2021-01-26 Tokyo Institute Of Technology oligonucleotídeo antissenso com toxicidade reduzida
WO2023027065A1 (ja) 2021-08-24 2023-03-02 日産化学株式会社 ２'修飾グアノシン化合物の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) * 1986-10-28 1990-09-19 The Johns Hopkins University Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
EP0942000B1 (en) * 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
JP2580091B2 (ja) * 1990-01-11 1997-02-12 アイシス・ファーマシューティカルス・インコーポレーテッド Ｒｎａ活性および遺伝子発現を検出および変調するための組成物および方法
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
JPH0813274B2 (ja) * 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
ATE515510T1 (de) * 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
DE69333842T2 (de) * 1992-07-23 2006-04-27 Isis Pharmaceuticals, Inc., Carlsbad Neue 2'-O-Alkyl-Nukleoside und -Phosphoramidite, Verfahren zu ihrer Herstellung und ihre Verwendungen

Also Published As

Publication number Publication date
US5969116A (en) 1999-10-19
JP4012579B2 (ja) 2007-11-21
DE59407895D1 (de) 1999-04-15
DK0626387T3 (da) 1999-09-27
AU6304494A (en) 1994-11-17
CA2123241A1 (en) 1994-11-13
IL123330A0 (en) 1998-09-24
JPH072889A (ja) 1995-01-06
AU687796B2 (en) 1998-03-05
EP0626387A1 (de) 1994-11-30
EP0626387B1 (de) 1999-03-10
IL109605A0 (en) 1994-08-26
CA2123241C (en) 2007-02-13
ATE177430T1 (de) 1999-03-15
ES2128535T3 (es) 1999-05-16
CN1100728A (zh) 1995-03-29
IL123330A (en) 1999-12-31

Similar Documents

Publication Publication Date Title
IL109605A (en) Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them
MY107655A (en) Derivatives of benzofuran,benzothiophene,indole and indolizine,process for their preparation as well as the compositions containing them
AU658781B2 (en) Substituted azoles and processes for the preparation thereof
CA2143040A1 (en) The use of benzazoles as uv absorbers, new benzazoles and a process for their preparation
HU9502811D0 (en) N-acyl-sulfamic acid esters (or thioesters), n-acyl-sulfonamides and n-sulfonyl-carbamic-acid-esters (or thioesters) as hypercholesterolemic agents
CA2081299A1 (en) Foaming agent composition and process
FI104176B1 (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
ES8301927A1 (es) Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales
EP0507337A3 (en) Novel erucyl, brassidyl and nervonyl derivatives
CA2280039A1 (en) Rinse added laundry additive compositions having color care agents
HUT61773A (en) Process for producing spicamycin derivatives and pharmaceutical compositions containing them as active components
DK0816368T3 (da) Kemisk phosphorylering af oligonukleotider og reaktanter anvendt dertil
CA2020097A1 (en) Azetidines, their preparation and their application as intermediates for the preparation of compounds with antimicrobial activity
ES8404151A1 (es) Procedimiento para la preparacion de nuevos derivados de acidos (di)-tiofosforicos y fosfonicos.
ZA942964B (en) Pyrrolopyrazine compounds processes for their preparation and the pharmaceutical compositions which contain them
CA2042745A1 (en) Novel hardenable compositions
ES8609184A1 (es) Procedimiento de preparar agentes de fluoracion de compuestos organicos.
DE69210639D1 (de) 3-(3,3,3-Trifluor-2-Chlorpropenyl)-2,2-Dimethylcyclopropancarbonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung als Pestitzide
TW368519B (en) Anhydrous fluorescent whitening agent composition
GB2342351A (en) Calixarene tubes as cation receptors
WO1994009011A1 (de) Quartäre ammoniumgruppen enthaltende siloxanderivate, verfahren zu ihrer herstellung und ihre verwendung
ES8205811A1 (es) Procedimiento para la preparacion de compuestos de triorganoestano-triacina
IE812876L (en) Ethers of substituted hydroxymethylpyrazines
ES2001701A6 (es) Un metodo para preparar compuesto de benzoilurea
GR3019075T3 (en) Inhibitor of herpes simplex viral thymidine kinase

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees